 |
 |
 |
 |
 |
 |
 |
PhiloGene focus on the discovery and development of protein therapeutics has led to the designation of three anti- angiogenic lead candidates for clinical development. Our most advanced product, PLG101, has application to both wet forms of age-related macular degeneration (AMD) and diabetic retinopathy. PLG201 and PLG202 are being developed for solid tumor cancer. PhiloGene is also in the discovery phase of a series of new compounds designed to regulate the balance between pro- and anti-angiogenic forms of VEGF.
In the eye, the native antagonist of VEGFR is more than a stoichiometric inhibitor of VEGFR. PLG101 is a pleiotropic factor acting as an anti-angiogenic factor, a survival factor for the retinal cells and a neuroprotective factor. It causes VEGF receptor internalization and degradation and reduces the blood vessels permeability. Therefore, patient with ophthalmic disorder have a chance to benefit from a treatment that is not only anti-angiogenic (as mAbs) but also controls the fluid dynamics in the eye and acts as a survival factor for the neural and pigmented retinal cells. Efficacy studies in rabbit corneal angiogenesis assay, hypoxia driven angiogenesis in mice, and transgenic mice expressing VEGF165 under the control of the lens specific á-crystalline promoter revealed that PLG101 is a potent and safe drug.
Status of Development:
Chemistry, Manufacturing and Controls development is ongoing. Toxicological studies will be completed in Q2 2008.
PLG201 has been found to inhibit the growth of number of different tumor types such as prostate carcinoma, Ewing’s sarcoma, renal cell carcinoma and melanoma in xenograft mouse tumor models.
Status of Development:
Process development of PLG202 is ongoing.
Coming Soon...
